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diagnose celiac disease: a retrospective analysis
of combined antibody tests
Annemarie Bürgin-Wolff1, Buser Mauro2 and Hadziselimovic Faruk1*Abstract
Background: The objective of this study was to compare celiac disease (CD)– specific antibody tests to determine
if they could replace jejunal biopsy in patients with a high pretest probability of CD.
Methods: This retrospective study included sera from 149 CD patients and 119 controls, all with intestinal biopsy.
All samples were analyzed for IgA and IgG antibodies against native gliadin (ngli) and deamidated gliadin peptides
(dpgli), as well as for IgA antibodies against tissue transglutaminase and endomysium.
Results: Tests for dpgli were superior to ngli for IgG antibody determination: 68% vs. 92% specificity and 79% vs.
85% sensitivity for ngli and dpgli, respectively. Positive (76% vs. 93%) and negative (72% vs. 83%) predictive values
were also higher for dpgli than for ngli. Regarding IgA gliadin antibody determination, sensitivity improved from
61% to 78% with dpgli, while specificity and positive predictive value remained at 97% (P < 0.00001). A
combination of four tests (IgA anti-dpgli, IgG anti-dpgli, IgA anti- tissue transglutaminase, and IgA
anti-endomysium) yielded positive and negative predictive values of 99% and 100%, respectively and a likelihood
ratio positive of 86 with a likelihood ratio negative of 0.00. Omitting the endomysium antibody determination still
yielded positive and negative predictive values of 99% and 98%, respectively and a likelihood ratio positive of 87
with a likelihood ratio negative of 0.01.
Conclusion: Antibody tests for dpgli yielded superior results compared with ngli. A combination of three or four
antibody tests including IgA anti-tissue transglutaminase and/or IgA anti- endomysium permitted diagnosis or
exclusion of CD without intestinal biopsy in a high proportion of patients (78%). Jejunal biopsy would be necessary
in patients with discordant antibody results (22%). With this two-step procedure, only patients with no CD-specific
antibodies would be missed.Background
Celiac disease (CD) is an immune-mediated enteropathy
that is caused by intolerance to gluten in genetically sus-
ceptible individuals. Its prevalence among the European
population is approximately 1% [1,2], and is even higher
among the elderly [3]. Thus, CD is one of the most fre-
quently occurring lifelong diseases. Serological tests to
diagnose CD have improved substantially in the last
20 years. In 1998 [4], we proposed a low-risk and cost-
effective algorithm to diagnose various forms of
gluten-sensitive enteropathy that achieved a positive
predictive value (ppv) of 99%, using a combination of* Correspondence: faruk@magnet.ch
1Institute for Celiac disease, Bahnhofplatz 11, 4410, Liestal, Switzerland
Full list of author information is available at the end of the article
© 2013 Bürgin-Wolff et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumdifferent antibody determinations: anti-endomysium
(EMA), IgA anti-tissue transglutaminase (IgA anti-
tTG), and IgA and IgG anti-native gliadin (IgA and
IgG anti-ngli). In a population with a high pretest
probability of disease, synchronous determination of
three or four CD-specific antibodies has a very high
ppv and negative predictive value (npv), and may eli-
minate the necessity of small-bowel biopsy in many
patients suspected of having CD [4].
In recent years, the use of ngli as an antigen in
antibody-detection tests has been replaced with deami-
dated gliadin peptides (dpgli), which perform better
diagnostically than ngli [5-12]. Our goal in this study was
to investigate whether using dpgli instead of ngli, alone or
in combination with other tests (EMA and IgA anti-tTG),ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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CD patients during the diagnostic procedure.Methods
Patients
Included in this retrospective study were serum samples
from 268 patients on a gluten-containing diet. The sam-
ples were collected in hospitals or medical services
throughout Switzerland, Germany and Austria. The sera
were then sent to the Institute for Coeliac Disease in
Liestal, Switzerland, where the antibody determinations
were performed without any knowledge of each patient’s
clinical condition. All patients from whom we received a
jejunal histology report and clinical data were included
in the study. At the beginning of our studies, all patients
with symptoms suggestive of CD underwent small intes-
tinal biopsy; antibody determinations were performed at
the same time. This diagnostic procedure gradually
changed with time as serological tests gained increasing
importance in diagnosis, and for an undefined period
patients were sometimes selected for biopsy when IgA
anti tTG or EMA were positive. The patients suffered
from gastrointestinal symptoms such as diarrhea, consti-
pation, poor weight gain, chronic vomiting, abdominal
pain, flatulence, and failure to thrive; or disorders such
as unexplained weight loss in adults, iron-deficiency
anemia, lassitude, psychiatric disorders, short stature,
and diabetes type 1. IgA-deficient CD patients were
excluded. Serum for antibody determinations was
obtained within 2 months before or one month after
endoscopic intervention.Sample analysis
All samples were analyzed for antibodies against tTG,
ngli, and dpgli by fully automated fluoroenzyme im-
munoassay tests (Elia Celikey IgA, Elia Gliadin IgA, Elia
Gliadin IgG, Elia Gliadin DP IgA and Elia Gliadin DP
IgG; Phadia [now Thermo Fisher Scientific], Freiburg,
Germany) performed on the Phadia 100 instrument in
accordance with the manufacturer’s instructions. With
the help of ROC curves, we calculated the optimal cut-
off values for our sample. For all analyzes except IgA
anti-dgpli, we found the best sensitivity and specificity to
be consistent with the recommendations of the respect-
ive manufacturer. For IgA anti- dpgli. we found that
using a cut off value of 7 instead of 10 resulted in some-
what higher sensitivity (78% instead of 71%) while main-
taining the same specificity.
For each antigen, we determined the best cut-off value
within our sample with respect to the sum of false-
positive and false-negative results: IgA anti tTG = 7, IgA
anti-ngli= 7, IgG anti-ngli = 7, IgA anti-dpgli = 7, and
IgG anti-dpgli = 10. EMA was analyzed by indirectimmunofluorescence on monkey esophagus sections:
cut-off = serum dilution: 1:5.
Statistical analysis
In addition to the usual descriptors for diagnostic tests,
such as sensitivity, specificity, and positive and negative
predictive values, the quantity “efficiency” was used: the
efficiency of a diagnostic test is its percentage of correct
outcomes. Because predictive values are dependent on
the prevalence of the disease in the study population, we
also calculated the positive and negative likelihood ratios
for CD, which are independent of the pretest probability
of disease. The likelihood ratio is the ratio of the prob-
ability that a patient with the disease has a particular test
result divided by the probability that a patient without
the disease has the same test result. Contingency tables
were evaluated using “Fisher’s Exact Test”. To test whether
the replacement or addition of a diagnostic test improves
the outcome to a statistically significant degree, McNemar’s
test for significant changes was applied. Both tests were
used in their precise form (not only asymptotic) as avail-
able in the software package StatXact version 6.3.0. (Cytel
Software Corporation Cambridge, MA, USA).
Results
The histology of 149 consecutive patients (104 females,
age range at biopsy 0.9–80 years, median age 29 years;
45 males, age range at biopsy 2–73 years, median age
13 years) revealed subtotal or complete villous atrophy,
hyperplasia of the crypts, and an increase in intraepithe-
lial lymphocytes (Marsh classification 3a, b, or c lesions).
All of these patients recovered after starting a gliadin-
free diet and were regarded as having CD. The biopsies
of 119 consecutive patients (66 females, age range at bi-
opsy 1.5–72 years, median age 17 years; 53 males, age
range at biopsy 2–66 years, median age 7 years) revealed a
normal mucosa or a mucosa with slight, nonspecific
changes; these patients were considered free of CD and
served as controls (The Control group was younger than
the group with CD, P=0.0074).
Deamidated gliadin peptides compared with native
gliadins as antigens
Sera from 149 patients with CD and 119 control patients
were tested for IgG and IgA antibodies against dpgli and
ngli proteins. IgG antibody determination for dpgli was
superior to that for ngli. Specificity was 68% vs. 92% and
sensitivity was 79% vs. 85% for ngli and dpgli, respect-
ively; ppv was 76% vs. 93% and npv was 72% vs. 83% for
ngli and dpgli, respectively. For IgA antibody determin-
ation, sensitivity was 61% vs. 78% for ngli and dpgli, re-
spectively, while the specificity and ppv remained at a
high level of 97% (McNemar’s test for significant
changes P < 0.00001, Table 1). Because dpgli antigens
Table 1 Antibody tests against deamidated gliadin










Sensitivity 61% 78% 79% 85%
Specificity 97% 97% 68% 92%
Positive predictive
value
97% 97% 76% 93%
Negative predictive
value
67% 78% 72% 83%
McNemar’s test for significant changes p < 0.00001.
61 correct changes; 154 remain correct; 7 wrong changes; 46 remain wrong.
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ther CD-specific antibody determinations.
Antibody profile in CD and control patients
We also determined the levels of IgA anti-tTG and
EMA in sera from the 149 CD patients and 119 controls
(Table 2). Because the IgA anti-tTG and EMA results
were comparable, we have omitted the EMA results; in-
stead, we have shown the IgA anti- tTG, and IgA anti-
dpgli, and IgG anti-dpgli antibody levels of each individual
and compared them with the histological result. We used a
multiple test consisting of three individual tests, which pro-
duce a total of eight possible results. We defined the out-
come of the multiple tests as positive only when all three
individual tests were above the cut-off, and as negative only
when all three individual tests were below the cut-off. The
majority of the patients (208/268) had either positive (110)
or negative (98) results in all three tests. Nearly all patients
(109/110) who tested positive for antibodies in all three
tests had CD according to histological findings. The ppv
was 99% in our population, with a CD frequency of 59%
(Table 3). Patients who did not test positive for CD-specific
antibodies in any of the three tests were almost all free of
CD according to the results of jejunal biopsy (96/98Table 2 Antibody profile in each of 149 CD patients and 119
IgA anti- tTG IgA anti- dpgli IgG anti- dpgli CD n = 1
+ + + 109
+ + - 7
+ - + 15
+ - - 13
- + + 0
- + - 0
- - + 3
- - - 2
+ antibody present; - antibody absent.patients); the npv was 98%. Patients with discordant anti-
body results (60/268 patients, 22%) could not be defined as
positive or negative for CD with the multiple tests and
remained unclassified. The likelihood positive ratio (lr+)
was 87 and the likelihood ratio negative (lr-) was 0.01
(Table 3). These findings indicate that a biopsy is avoidable
if all antibody values are either above or below the cut-off.
In patients with discordant antibody results, an intestinal
biopsy is necessary to diagnose or exclude CD.
Performance of single antibody tests and selected test
combinations
We compared the performance of IgA anti-dpgli, IgG
anti-dpgli, IgA anti-tTG, and EMA tests, and calculated
the sensitivity, specificity, ppv, npv, lr+, lr-, and efficiency
of each test and some of the possible test combinations
(Table 3). We also indicated the absolute number of
patients whose antibody test results were falsely positive
or falsely negative for CD, as well as those who could
not be classified based on antibody tests. Most of the
following diagnostic tests are multiple tests (compare
with Table 2). We defined the outcome of a multiple test
as positive only when all individual tests were above the
cut-off, and as negative only when all individual tests
were below the cut-off. Test combinations containing
only IgA antibodies were not considered; they are un-
suitable for diagnostic purposes, because of the possibi-
lity that some patients may be deficient in IgA.
Currently, biopsies are often performed when a
patient’s IgA anti-tTG or EMA test is positive. Negative
serological results are usually not followed by a jejunal
intervention, unless there is a very strong clinical suspi-
cion of CD. However, the data in Table 3 clearly show
that single tests are neither specific nor sensitive enough
to reduce the number of biopsies in patients with symp-
toms of CD, although the number of nonclassified patients
was zero. Single tests such as the widely used IgA anti-
tTG test can give rise to many falsely classified patients.controls
49 Controls n = 119 Total n = 268 Classification
1 110 110 positives
1 8
4 19




96 98 98 negatives
Table 3 Performance of single antibody tests and selected combinations n = 268, 149 CD patients and 119 controls
fn fp nc sens spec ppv npv effic lr+ lr-
Single tests % % % % %
IgA anti-dpgli 33 4 0 78 97 97 78 86 23 0.23
IgG anti-dpgli 22 10 0 85 92 93 83 88 10 0.16
IgA anti-tTG 5 16 0 97 87 90 95 92 7 0.04
EMA 3 18 0 98 85 89 97 98 6 0.02
Combinations of 2 tests
IgG anti-dpgli +
IgA anti-tTG 2 5 39 83 82 96 98 83 20 0.04
IgG anti-dpgli + EMA 1 6 39 84 82 95 99 83 17 0.01
IgA anti-dpgli + IgG anti-dpgli 15 1 37 73 89 99 88 80 87 0.11
Combinations of 3 tests
IgA anti-dpgli +
IgG anti-dpgli + EMA 1 1 62 72 81 99 99 76 86 0.01
IgA anti-dpgli + IgG anti-dpgli + IgA anti-tTG* 2 1 60 73 81 99 98 76 87 0.01
IgG anti-dpgli + EMA + IgA anti-tTG 0 5 45 83 80 96 100 81 20 0.00
Combination of 4 tests
IgG anti-dpgli +
IgA anti-dpgli + EMA + IgA anti-tTG 0 1 65 72 79 99 100 75 86 0.00
*This test combination is identical to the test in Table 2.
Positive, above the cut-off in all tests; negative, below the cut-off in all tests; fn, number of false-negative patients; fp, number of false-positive patients; nc,
number of patients not classified because of discordant antibody results; sens, sensitivity; spec,specificity; ppv, positive predictive value; npv, negative predictive
value; effic, efficiency; lr+, likelihood ratio positive; lr-, likelihood ratio negative.
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rectly classified patients and is therefore unsuitable for
reducing the number of biopsies. The two-test combina-
tions yielded either too many false-positive diagnoses
(IgG anti-dpgli + IgA anti-tTG or IgG anti-dpgli +
EMA) or too many false-negative diagnoses (IgA anti-
dpgli + IgG anti- dpgli), although the number of non-
classified patients was smaller than in combinations with
more than two tests. The combination of four tests was
optimal: only one patient was falsely positive, no patients
were falsely negative, the ppv was 99%, the npv was
100%, the lr+ was 86, and the lr- was 0.00 For practical
reasons, a combination of three tests using IgA anti-tTG
instead of EMA in combination with IgA anti-dpgli and
IgG anti-dpgli (Table 2) may be sufficient to set a stand-
ard (ppv 99%, one false-positive result; npv 98%, two
false-negative results; and lr+ = 87, lr- = 0.01). A biopsy
was avoidable in 208/268 patients (78%), while 60/268
patients (22%) could not be diagnosed with the combi-
nation of serological tests because their results were in
disagreement (only one or two results above the cut-off,
with the remaining result(s) below the cut-off; Table 2).
Discussion
The diagnosis of CD has traditionally depended upon
intestinal biopsies and has been extended to include an
array of serological markers. The guidelines of the European
and North American societies for gastroenterology requirea biopsy for diagnosis [13,14]. Recently, the European So-
ciety for Pediatric Gastroenterology, Hepatology, and Nu-
trition published guidelines allowing the diagnosis of CD
without a biopsy in some situations [15]. CD is usually
diagnosed when the duodenal and jejunal mucosa display
villous atrophy, crypt hyperplasia, and an increase in
intraepithelial lymphocytes [16-19]. However, different
diseases not related to gluten- sensitive enteropathy can
induce a flat mucosa, thus mimicking CD. Moreover,
patients with gluten-sensitive enteropathy and normal
small bowel mucosal architecture have also been
described [20-24]. Most likely because of a lack of tech-
nical proficiency with grasping biopsy forceps or endo-
scopic procedure, biopsy specimens have been shown to
be sufficient for diagnosis of CD in only 90% of cases [25].
Furthermore, CD may be missed during histological
examinations owing to variations in different pathologists’
assessments [26]. Because of this, and because of the in-
convenience and high cost associated with jejunal biopsy
and the high prevalence of CD in the general population,
less-invasive tests are required. In the last 20 years, sero-
logical tests for the diagnosis of CD have improved sub-
stantially [27-33]. For practical and ethical reasons,
patients with negative serology sometimes did not
undergo a biopsy unless clinical indications of CD were
evident. This procedure causes a verification bias because
the gold standard (histology of the mucosa) is not always
available for negative tests [29]. On the other hand, a
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was only a slight clinical suspicion of CD. Today, it is
nearly impossible to overcome this bias for ethical rea-
sons; therefore, the bias may be present in many studies.
The data contained in Table 3, however, indicate that
the criteria for choosing the best tests must be defined.
For clinicians who want to reduce the number of jejunal
interventions in a population with a high frequency of
CD, the best test is the one with the lowest sum of false-
positive and false-negative diagnoses: the test with the
highest ppv, the highest npv, a high likelihood ratio posi-
tive, and a low likelihood ratio negative. In our study, a
combination of four antibody tests yielded a ppv of 99%,
an npv of 100%, an lr+ of 86, and an lr- of 0.00. For
practical reasons, we may omit EMA from our combi-
nation of antibody tests, and instead chose the test com-
bination of IgG anti-dpgli + IgA anti-dpgli + IgA anti-tTG
(Tables 2 and 3), with a ppv of 99%, an npv of 98%, an
lr+ of 87, and an lr- of 0.01, as the first step in our
diagnostic procedure. Out of 268 patients, 208 (78%)
were correctly classified with these serological tests:
they had either three tests above or three tests below
the cut- off. Intestinal biopsy was necessary as a se-
cond diagnostic step in the remaining 60 patients
(22%), who had discordant antibody results. This two-
step diagnostic procedure reduces the number of intes-
tinal biopsies and increases the sensitivity of the entire
diagnostic procedure; only CD patients without any CD-
specific antibodies would be missed.
In 1998 [4], we suggested the above combination of
serological tests as a low-risk and cost-effective algo-
rithm for diagnosing various forms of CD. This combin-
ation — still using anti ngli — was confirmed in a total
of 1,873 patients with jejunal biopsy [30-32]. Because of
patient preselection according to their symptoms, the
prevalence of CD was 59%. The ppv of three tests with
congruent positive antibody results was >99%. The npv
of all three antibody tests was 98%. However, 37% (599/
1,873) of the patients with discordant antibody results
could not be classified by antibody tests alone. In the
present study, the number of nonclassified patients was
reduced from 37% to 22% (P < 0.001) because anti-dpgli
performed better than anti-ngli. Thus, in a population
with a high pretest probability of CD, using a combi-
nation of three or four antibody tests should obviate the
need for as many as 78% of jejunal biopsies.
Several recent studies have questioned the necessity of
performing a jejunal biopsy on all individuals with sus-
pected CD [34-39]. One approach defined five criteria,
including clinical signs, four of which had to be fulfilled
for a diagnosis of CD [38]. Other studies describe the as-
sociation of very high IgA anti-tTG antibody titers with
Marsh 3 histopathology [35-37]. Therefore, recent guide-
lines, released by the European Society for PediatricGastroenterology, Hepathology, and Nutrition stated
that intestinal biopsy is redundant in patients with high
anti-tTG antibody titers (>10 times the upper limit of
normal) [15]. These proposals attain a high specificity
and will result in few patients receiving a false-positive
diagnosis. However, many CD patients do not have such
high anti-tTG titer, and will therefore require intestinal
biopsy. Sugai et al. [39] investigated single antibody tests
and various combinations of two-antibody tests in popu-
lations with different pretest probabilities for CD. As in
our study, sensitivity was lower in combined tests than
in single tests; however, ppv increased significantly
not only in the population with high pretest probabi-
lity for CD, but also in the group with low pretest
probability for CD. They concluded that: “Appro-
priate use of CD serology might accurately identify
the vast majority of CD patients in populations with
different pretest probabilities”.
Recently, Vermeersch et al. illustrated the utility of
likelihood ratios for the interpretation of CD serology.
[40] The likelihood ratio for CD was much higher for
double positive test than for single positive test results.
[40] Our results showed comparable test results for single
and double positive analyses. (Table 3) Similarly, triple
positive tests had a high likelihood ratio. However, the
best test for CD exclusion was the triple negative test
which had a significantly lower likelihood ratio than the
double negative test reults reported by Vermeersch et al.
(p=0.000037).
Therefore, we speculate that the combined tests with
the very high likelihood ratio positive and the very low
likelihood ratio negative achieved in the present study
group will also identify patients in populations with a
low CD frequency.
Conclusion
There is no single test — not even jejunal biopsy — that
can conclusively diagnose or exclude CD in every indi-
vidual. Therefore, we propose the following two-step
diagnostic procedure: The first step is the combined,
simultaneous determination of IgA anti-dpgli and IgG
anti-dpgli + IgA anti-tTG and/or EMA. The vast majority
of patients will have either three positive or three negative
results, obviating the need for a biopsy. The second step,
jejunal biopsy, should be performed only in patients with
discordant antibody results (i.e., in patients whose CD sta-
tus cannot be classified by antibody tests alone). In any
case, effects of a gluten-free diet must be controlled.
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